Sumitomo Pharma Co., Ltd. (DNPUF) 은(는) 상장 기업입니다 헬스케어 섹터의 Drug Manufacturers - Specialty & Generic 산업에서 운영. 본사 소재지는 Osaka, 일본. 현재 CEO는 Toru Kimura.
DNPUF 을(를) 보유 IPO 날짜 2012-01-17, 4,980 명의 정규직 직원, 에 상장 Other OTC, 시가총액 $4.41B.
Sumitomo Pharma Co., Ltd. is a Japan-based pharmaceutical manufacturer and supplier operating globally across North America, China, and other international markets. The company develops and markets a diverse therapeutic portfolio including treatments for Parkinson's disease, depression, type 2 diabetes, cancer, infectious diseases, and cardiovascular conditions, alongside specialty pharmaceuticals for rare diseases such as Fabry disease. Beyond pharmaceuticals, Sumitomo Pharma produces food ingredients and additives, chemical materials for industrial and personal care applications, and veterinary medicines for both companion and livestock animals. Founded in 1897 and headquartered in Osaka, the company maintains strategic partnerships with leading research institutions including Kyoto University, RIKEN, and the Center for iPS Cell Research, as well as collaborations with biotech firms such as Roivant Sciences. As a subsidiary of Sumitomo Chemical Company, Limited, Sumitomo Pharma combines established pharmaceutical expertise with innovation in emerging therapeutic areas.
